Revolution Medicines, Inc.
RVMD
$99.00
$4.144.36%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 56.80% | 72.98% | 49.71% | 74.33% | 37.72% |
| Gross Profit | -56.80% | -72.98% | -49.71% | -74.33% | -38.47% |
| SG&A Expenses | 136.35% | 120.21% | 86.91% | 53.30% | 51.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 67.18% | 79.42% | 68.99% | 70.92% | 39.35% |
| Operating Income | -67.18% | -79.42% | -68.99% | -70.92% | -40.02% |
| Income Before Tax | -86.82% | -95.28% | -85.98% | -83.97% | -21.17% |
| Income Tax Expenses | -- | -- | -- | -- | -319.53% |
| Earnings from Continuing Operations | -87.54% | -95.28% | -85.98% | -83.97% | -20.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -87.54% | -95.28% | -85.98% | -83.97% | -20.45% |
| EBIT | -67.18% | -79.42% | -68.99% | -70.92% | -40.02% |
| EBITDA | -67.46% | -79.92% | -69.68% | -71.58% | -40.11% |
| EPS Basic | -65.69% | -72.19% | -62.85% | -61.08% | 2.13% |
| Normalized Basic EPS | -65.04% | -72.16% | -62.87% | -61.08% | -16.96% |
| EPS Diluted | -65.69% | -72.19% | -62.85% | -61.08% | 2.13% |
| Normalized Diluted EPS | -65.04% | -72.16% | -62.87% | -61.08% | -16.96% |
| Average Basic Shares Outstanding | 13.19% | 13.42% | 14.19% | 14.22% | 23.07% |
| Average Diluted Shares Outstanding | 13.19% | 13.42% | 14.19% | 14.22% | 23.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |